On November 8-9, 2022, the IMS hosted the first joint symposium with the FDA, which provided a forum for open discussion among academia, industry, and regulatory agencies on clinical drug development in multiple myeloma. The 2022 IMS-FDA Joint Workshop— Future of Drug Development in Multiple Myeloma
—focused on trial design, patient population, and endpoints in different multiple myeloma disease settings.
In 2024, the IMS held another joint workshop with the FDA— Defining Patient Populations for Clinical Studies in Multiple Myeloma— focused on identifying challenges and formulating potential solutions for clinical development of novel myeloma therapies in the contemporary era of triplet and quadruplet upfront treatments and innovative T-cell–directed immunotherapies.

Why Become a Member

The International Myeloma Society is a professional, scientific, and medical society established to bring together clinical and experimental scientists involved in the study of myeloma. The purpose of this society is to promote research, education, clinical studies (including diagnosis and treatment), workshops, conferences, and symposia on all aspects of multiple myeloma worldwide.

The IMS is a membership organization comprised of basic research scientists, and clinical investigators in the field along with physicians and other healthcare practitioners.

Login
See All of the Member Benefits
Become a Member Today

Stay updated